Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
| Buy | Overweight | Hold | Underweight | Sell |
|---|---|---|---|---|
| 20 | 6 | 3 | 0 | 1 |
Analyst Firms Making Recommendations1
- Morgan Stanley
- Wells Fargo
- Raymond James
- Barclays
- Mizuho
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Abbott Laboratories
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10/19/2023 | ABT | Buy Now | Abbott Laboratories | $101.86 | 5.05% | Morgan Stanley | David Lewis | $112 → $107 | Maintains | Equal-Weight | Get Alert |
| 10/19/2023 | ABT | Buy Now | Abbott Laboratories | $101.86 | 13.88% | Wells Fargo | Lawrence Biegelsen | $136 → $116 | Maintains | Overweight | Get Alert |
| 10/19/2023 | ABT | Buy Now | Abbott Laboratories | $101.86 | 7.99% | Raymond James | Jayson Bedford | $123 → $110 | Maintains | Outperform | Get Alert |
| 07/24/2023 | ABT | Buy Now | Abbott Laboratories | $101.86 | 29.59% | Barclays | Matt Miksic | $127 → $132 | Maintains | Overweight | Get Alert |
| 07/21/2023 | ABT | Buy Now | Abbott Laboratories | $101.86 | 9.95% | Morgan Stanley | David Lewis | $112 → $112 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 07/21/2023 | ABT | Buy Now | Abbott Laboratories | $101.86 | 12.9% | Mizuho | Anthony Petrone | $110 → $115 | Assumes | Neutral → Neutral | Get Alert |
| 07/21/2023 | ABT | Buy Now | Abbott Laboratories | $101.86 | — | Wolfe Research | Mike Polark | — | Upgrade | Underperform → Peer Perform | Get Alert |
| 04/20/2023 | ABT | Buy Now | Abbott Laboratories | $101.86 | 27.63% | UBS | Matthew Korn | $117 → $130 | Maintains | Buy | Get Alert |
| 04/20/2023 | ABT | Buy Now | Abbott Laboratories | $101.86 | 20.75% | Raymond James | Jayson Bedford | $116 → $123 | Maintains | Outperform | Get Alert |
| 04/20/2023 | ABT | Buy Now | Abbott Laboratories | $101.86 | 24.68% | Barclays | Matt Miksic | $125 → $127 | Maintains | Overweight | Get Alert |
| 04/20/2023 | ABT | Buy Now | Abbott Laboratories | $101.86 | 27.63% | Citigroup | Joanne Wuensch | $125 → $130 | Maintains | Buy | Get Alert |
| 04/17/2023 | ABT | Buy Now | Abbott Laboratories | $101.86 | 27.63% | BTIG | Ryan Zimmerman | $125 → $130 | Maintains | Buy | Get Alert |
| 04/17/2023 | ABT | Buy Now | Abbott Laboratories | $101.86 | 13.88% | Raymond James | Jayson Bedford | $123 → $116 | Maintains | Outperform | Get Alert |
| 04/10/2023 | ABT | Buy Now | Abbott Laboratories | $101.86 | 33.52% | Wells Fargo | Lawrence Biegelsen | $140 → $136 | Maintains | Overweight | Get Alert |
| 04/05/2023 | ABT | Buy Now | Abbott Laboratories | $101.86 | 33.52% | Wells Fargo | Larry Biegelsen | $140 → $136 | Maintains | Overweight | Get Alert |
| 01/22/2022 | ABT | Buy Now | Abbott Laboratories | $101.86 | 22.72% | JP Morgan | Robbie Marcus | → $125 | Maintains | Overweight | Get Alert |
| 07/22/2022 | ABT | Buy Now | Abbott Laboratories | $101.86 | 22.72% | JP Morgan | Robbie Marcus | → $125 | Maintains | Overweight | Get Alert |
| 08/01/2021 | ABT | Buy Now | Abbott Laboratories | $101.86 | 27.63% | Jefferies | Raj Denhoy | $123 → $130 | Maintains | Buy | Get Alert |
| 08/23/2021 | ABT | Buy Now | Abbott Laboratories | $101.86 | 37.44% | TD Cowen | Joshua Jennings | $125 → $140 | Maintains | Outperform | Get Alert |
What is the target price for Abbott Laboratories (ABT)?
The latest price target for Abbott Laboratories (NYSE: ABT) was reported by Morgan Stanley on October 19, 2023. The analyst firm set a price target for $107.00 expecting ABT to rise to within 12 months (a possible 5.05% upside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Abbott Laboratories (ABT)?
The latest analyst rating for Abbott Laboratories (NYSE: ABT) was provided by Morgan Stanley, and Abbott Laboratories maintained their equal-weight rating.
When is the next analyst rating going to be posted or updated for Abbott Laboratories (ABT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Abbott Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Abbott Laboratories was filed on October 19, 2023 so you should expect the next rating to be made available sometime around October 19, 2024.
Is the Analyst Rating Abbott Laboratories (ABT) correct?
While ratings are subjective and will change, the latest Abbott Laboratories (ABT) rating was a maintained with a price target of $112.00 to $107.00. The current price Abbott Laboratories (ABT) is trading at is $101.86, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.